Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 51, 3768-3773, July 15, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stastny, J. J.
Right arrow Articles by Das Gupta, T. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stastny, J. J.
Right arrow Articles by Das Gupta, T. K.

Monoclonal Antibody Identification and Characterization of Two Human Sarcoma-associated Antigens1

Jaroslav J. Stastny, John M. Brown2, Craig W. Beattie and Tapas K. Das Gupta3

Specialized Center for Cancer Research and Education, University of Illinois College of Medicine at Chicago, Chicago, Illinois 60612

Two murine monoclonal antibodies, 29–13 (IgG1) and 29–2 (IgG2a), generated against malignant fibrous histiocytoma plasma membranes immunoprecipitated a Mr 200,000 protein (p200), with an isoelectric point between 6.3 and 7.5. Two additional antibodies, 35–16 (IgG1) and 30–40 (IgG2a), generated against Ewing's sarcoma membranes, immunoprecipitated an acidic protein of Mr 160,000 (p160), with an isoelectric point between 5.8 and 6.7. Monoclonal antibodies 29–13 and 29–2 recognize a similar determinant(s) on p200 while 35–16 and 30–40 recognize different determinants on p160.

Monoclonal antibody 29–13 exhibited significant binding to membranes isolated from fibrosarcoma and aggressive fibromatosis; moderate binding to osteosarcoma, hemangiopericytoma, and malignant fibrous histiocytoma; and minimal to no binding to other soft tissue sarcoma plasma membranes. The p200 protein was not expressed in 16 other malignant tumors and in only 3 of 35 normal human tissue specimens. High levels of p200 were selectively expressed by leiomyosarcoma, Ewing's sarcoma, and fibrosarcoma cells as well as neonatal fibroblasts in vitro, but not by other carcinoma cell lines or B-lymphoblasts.

The p160 protein appeared to be selectively expressed by Ewing's sarcoma with little or no expression on other sarcomas, carcinomas, or normal tissues. However, the p160 antigen was expressed in Ewing's sarcoma, leiomyosarcoma, melanoma, 4 of 9 carcinomas, and neonatal fibroblasts in vitro.

The affinity of MoAbs 29–13, 29–2, 35–16, and 30–40 ranged from 5.3 x 102 to 4.7 x 109 M-1 for sarcoma membranes with approximately 5 x 104 binding sites/sarcoma cell.

1 Supported by USPHS Grant CA-35354 from the National Cancer Institute.

2 Present address: Centocor, Malvern, PA 19355.

3 To whom requests for reprints should be addressed, at Specialized Center for Cancer Research and Education, University of Illinois College of Medicine at Chicago, 840 South Wood Street, Chicago, IL 60612.

Received 1/28/91. Accepted 5/ 6/91.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1991 by the American Association for Cancer Research.